Evidence map›Paper›PMID 37834292›Full record

ArticleInternational journal of molecular sciences2023

Apolipoprotein-CIII

Annemieke Naber, Daniel Demus, Roderick Slieker, Simone Nicolardi, Joline W J Beulens, Petra J M Elders, Aloysius G Lieverse, Eric J G Sijbrands, Leen M 't Hart, Manfred Wuhrer and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Annemieke NaberDepartment of Internal Medicine, Erasmus MC University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.ORCID 0000-0002-2875-9858
Daniel DemusCenter for Proteomics and Metabolomics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Roderick SliekerDepartment of Cell and Chemical Biology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Simone NicolardiCenter for Proteomics and Metabolomics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.ORCID 0000-0001-8393-1625
Joline W J BeulensDepartment of Epidemiology and Data Science, Amsterdam UMC, Location Vrije Universiteit Amsterdam, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands.
Petra J M EldersDepartment of General Practice, Amsterdam Public Health Institute, Amsterdam UMC, Location VUmc, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands.
Aloysius G LieverseDepartment of Internal Medicine, Maxima Medical Center, P.O. Box 90052, 5600 PD Eindhoven, The Netherlands.
Eric J G SijbrandsDepartment of Internal Medicine, Erasmus MC University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.
Leen M 't HartDepartment of Cell and Chemical Biology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.ORCID 0000-0003-4401-2938
Manfred WuhrerCenter for Proteomics and Metabolomics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.ORCID 0000-0002-0814-4995
Mandy van HoekDepartment of Internal Medicine, Erasmus MC University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.
Leiden University Medical Center · NLErasmus MC · NLAmsterdam UMC Location Vrije Universiteit Amsterdam · NLRadboud University Nijmegen · NLUniversity Medical Center Utrecht · NL

Funding

European Union's Horizon 2020 research and innovation: Marie Skłodowska-Curie grant agreement No 722095.
6 · The paper itself

Abstract

Apolipoprotein-CIII (apo-CIII) is involved in triglyceride-rich lipoprotein metabolism and linked to beta-cell damage, insulin resistance, and cardiovascular disease. Apo-CIII exists in four main proteoforms: non-glycosylated (apo-CIII

Indexed as

Diabetes Mellitus, Type 2HyperlipidemiasHypertriglyceridemiaAdaptor Proteins, Signal TransducingApolipoprotein C-IIIApolipoproteins CCholesterol, HDLCytoskeletal ProteinsGenome-Wide Association StudyGlycosylationHumansReceptors, Cytoplasmic and NuclearTriglyceridesVesicular Transport ProteinsAdaptor Proteins, Signal TransducingApolipoprotein C-IIIApolipoproteins CCholesterol, HDLCytoskeletal ProteinsIFT172 protein, humanNRBP1 protein, humanReceptors, Cytoplasmic and NuclearTriglyceridesVesicular Transport Proteinsapolipoprotein C-IIIdiabetes mellitus type 2genome-wide association studyglycomicshypertriglyceridemia

Identifiers

PMID37834292
PMCPMC10573541
OpenAlexW4387266750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.